Success Metrics

Clinical Success Rate

100.0%

Based on 7 completed trials

Completion Rate

100%(7/7)

Active Trials

0(0%)

Results Posted

71%(5 trials)

Phase Distribution

Ph phase_2

29%

Ph phase_1

14%

Ph phase_3

57%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

2(28.6%)

Phase 3Large-scale testing

4(57.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (14.3%)

Phase 22 (28.6%)

Phase 34 (57.1%)

Trials by Status

completed7100%

Recent Activity

0 active trials

Showing 5 of 7

completedphase_3

Clinical Trials (7)

Showing 7 of 7 trials

NCT01991821Phase 3

European Phase III Study of APD421 in PONV

Completed

NCT02337062Phase 3

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Completed

NCT01510704Phase 2

Phase II Dose-ranging Study of APD421 in PONV

Completed

NCT02449291Phase 3

Study of APD421 as PONV Treatment (no Prior Prophylaxis)

Completed

NCT02646566Phase 3

Study of APD421 as PONV Treatment (Prior Prophylaxis)

Completed

NCT03583489Phase 1

Study of APD421 With and Without Ondansetron

Completed

NCT01303978Phase 2

Phase II Proof-of-concept Study of APD421

Completed

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7